<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0023">
 <label>23</label>
 <element-citation publication-type="journal" id="sbref0019">
  <person-group person-group-type="author">
   <name>
    <surname>Nishimoto</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Terao</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Mima</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Nakahara</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Takagi</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Kakehi</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Mechanisms andpathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease</article-title>
  <source>Blood</source>
  <volume>112</volume>
  <year>2008</year>
  <fpage>3959</fpage>
  <lpage>3964</lpage>
  <pub-id pub-id-type="pmid">18784373</pub-id>
 </element-citation>
</ref>
